{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:25:00Z","timestamp":1786991100599,"version":"build-2736575974"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332021007"],"award-info":[{"award-number":["3332021007"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.intimp.2022.108517","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T17:47:13Z","timestamp":1642528033000},"page":"108517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review"],"prefix":"10.1016","volume":"105","author":[{"given":"Yuanzhuo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baihui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gechong","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2022.108517_b0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/17474124.2019.1574569","article-title":"Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis","volume":"13","author":"Greuter","year":"2019","journal-title":"Exp. Rev. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108517_b0010","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/2050640620958902","article-title":"Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes","volume":"8","author":"Jansen","year":"2020","journal-title":"United European Gastroenterol. J."},{"issue":"5","key":"10.1016\/j.intimp.2022.108517_b0015","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","article-title":"The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy","volume":"13","author":"Hedin","year":"2019","journal-title":"J. Crohns. Colitis"},{"issue":"3","key":"10.1016\/j.intimp.2022.108517_b0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40265-020-01460-3","article-title":"Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease","volume":"81","author":"Hanzel","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.intimp.2022.108517_b0025","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/gutjnl-2020-322129","article-title":"Emerging treatment options for extraintestinal manifestations in IBD","volume":"70","author":"Greuter","year":"2021","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.intimp.2022.108517_b0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jbspin.2019.09.005","article-title":"Inhibition of JAK\/STAT signaling in rheumatologic disorders: The expanding spectrum","volume":"87","author":"El Jammal","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.intimp.2022.108517_b0035","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.intimp.2022.108517_b0040","doi-asserted-by":"crossref","first-page":"86","DOI":"10.33878\/2073-7556-2019-18-4-86-99","article-title":"Experience of tofacitinib using in therapy of ulcerative colitis in real clinical practice","volume":"18","author":"Belousova","year":"2019","journal-title":"Koloproktologia"},{"key":"10.1016\/j.intimp.2022.108517_b0045","doi-asserted-by":"crossref","first-page":"S1148-S","DOI":"10.14309\/01.ajg.0000597736.21235.a9","article-title":"Tofacitinib Improves Refractory Crohn's Disease-Associated Arthritis","volume":"114","author":"Gordon","year":"2019","journal-title":"Am. J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108517_b0050","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/ibd\/izz015","article-title":"Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab","volume":"25","author":"Gregory","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"issue":"5","key":"10.1016\/j.intimp.2022.108517_b0055","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","article-title":"Tofacitinib for the Treatment of Pyoderma Gangrenosum","volume":"17","author":"Kochar","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108517_b0060","doi-asserted-by":"crossref","first-page":"S881-S","DOI":"10.1016\/S0016-5085(19)39173-5","article-title":"Combination therapy of vedolizumab and tofacitinib in IBD patients with chronic active refractory disease course and spondylarthritis","volume":"156","author":"Kuehbacher","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.intimp.2022.108517_b0065","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cgh.2018.08.017","article-title":"Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy","volume":"17","author":"Le Berre","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108517_b0070","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000226","article-title":"Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis","volume":"6","author":"Wang","year":"2019","journal-title":"Acg Case Rep. J."},{"issue":"7","key":"10.1016\/j.intimp.2022.108517_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072177","article-title":"Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study","volume":"9","author":"Hoffmann","year":"2020","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.intimp.2022.108517_b0080","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s12328-020-01150-3","article-title":"Two cases in which tofacitinib effectively treated both ulcerative colitis and alopecia areata","volume":"13","author":"Kikuchi","year":"2020","journal-title":"Clin. J. Gastroenterol."},{"issue":"24","key":"10.1016\/j.intimp.2022.108517_b0085","doi-asserted-by":"crossref","DOI":"10.12998\/wjcc.v8.i24.6389","article-title":"Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report","volume":"8","author":"Komeda","year":"2020","journal-title":"World J. Clin. Cases"},{"issue":"3","key":"10.1016\/j.intimp.2022.108517_b0090","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1053\/j.gastro.2019.11.273","article-title":"Real-world experience with tofacitinib for the management of crohn's colitis","volume":"158","author":"Kumar","year":"2020","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.intimp.2022.108517_b0095","doi-asserted-by":"crossref","first-page":"1125-+","DOI":"10.1136\/annrheumdis-2019-216606","article-title":"Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis","volume":"79","author":"Kuwabara","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2022.108517_b0100","doi-asserted-by":"crossref","first-page":"E146-E","DOI":"10.1093\/ibd\/izaa158","article-title":"Treatment of Ulcerative Colitis and Seronegative Inflammatory Spondyloarthritis With Vedolizumab and Tofacitinib","volume":"26","author":"Lee","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"issue":"6","key":"10.1016\/j.intimp.2022.108517_b0105","doi-asserted-by":"crossref","first-page":"S450","DOI":"10.1016\/S0016-5085(20)31809-6","article-title":"Colitis patients with PSC may gain additional benefit from the use of tofacitinib","volume":"158","author":"Lewis","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2022.108517_b0110","doi-asserted-by":"crossref","first-page":"S1211-S","DOI":"10.14309\/01.ajg.0000711212.36285.25","article-title":"Severe Cutaneous Lesions in Crohn's Disease Responsive to Combination Therapy, Ustekinumab and Tofacitinib","volume":"115","author":"Owings","year":"2020","journal-title":"Am. J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108517_b0115","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/kez580","article-title":"A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib","volume":"59","author":"Sato","year":"2020","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.intimp.2022.108517_b0120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.arbr.2019.08.006","article-title":"Ulcerative Colitis and Bronchiectasis: Can Treatment with Tofacitinib Have an Impact on Respiratory Symptoms?","volume":"56","author":"Xavier Leon-Roman","year":"2020","journal-title":"Arch. Bronconeumol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108517_b0125","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1093\/ibd\/izaa243","article-title":"Tofacitinib for the Treatment of Ulcerative Colitis, Alopecia Universalis, and Atopic Dermatitis: One Drug, Three Diseases","volume":"27","author":"Honap","year":"2021","journal-title":"Inflam. Bowel Dis."},{"key":"10.1016\/j.intimp.2022.108517_b0130","doi-asserted-by":"crossref","DOI":"10.1111\/ced.14683","article-title":"Tofacitinib for the treatment of refractory pyoderma gangrenosum","author":"Orfaly","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.intimp.2022.108517_b0135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdcr.2020.10.027","article-title":"Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease","volume":"7","author":"Peterson","year":"2021","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.intimp.2022.108517_b0140","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211005708","article-title":"Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis","volume":"14","author":"Rubin","year":"2021","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.intimp.2022.108517_b0145","series-title":"Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva","article-title":"Tofacitinib, useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient","author":"Salmon Olavarria","year":"2021"},{"issue":"5","key":"10.1016\/j.intimp.2022.108517_b0150","doi-asserted-by":"crossref","first-page":"E65-E","DOI":"10.1093\/ibd\/izab005","article-title":"Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata","volume":"27","author":"Sedano","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2022.108517_b0155","first-page":"4648627","article-title":"Salvaging the Digit in Invasive Subungual Malignancies Using a Triple Technique under Awake Local Anesthesia","volume":"2021","author":"Al","year":"2021","journal-title":"Case Rep. Orthop."},{"issue":"11","key":"10.1016\/j.intimp.2022.108517_b0160","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Beh\u00e7et's syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2022.108517_b0165","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1093\/rheumatology\/keaa281","article-title":"Tofacitinib in patients with refractory Takayasu's arteritis","volume":"59","author":"Li","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.intimp.2022.108517_b0170","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/annrheumdis-2019-215455","article-title":"Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre","volume":"78","author":"You","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.108517_b0175","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J. Dermatol. Sci."},{"issue":"18","key":"10.1016\/j.intimp.2022.108517_b0180","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"New England J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2022.108517_b0185","article-title":"First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"9","key":"10.1016\/j.intimp.2022.108517_b0190","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.15689","article-title":"Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry","volume":"51","author":"Biemans","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2022.108517_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108517_b0200","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2022.108517_b0205","article-title":"Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease","volume":"38\u201339","author":"Ma","year":"2019","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.intimp.2022.108517_b0210","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.intimp.2022.108517_b0215","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal Manifestations of Inflammatory Bowel Disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.108517_b0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"3","key":"10.1016\/j.intimp.2022.108517_b0225","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-017-0251-7","article-title":"Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment","volume":"18","author":"Alavi","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108517_b0230","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108517_b0235","first-page":"504","article-title":"Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor","volume":"179","author":"Nasifoglu","year":"2018","journal-title":"British J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108517_b0240","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108517_b0245","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","article-title":"Treatment of Alopecia Areata With Tofacitinib","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108517_b0250","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000494613","article-title":"Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study","volume":"235","author":"Almutairi","year":"2019","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"5","key":"10.1016\/j.intimp.2022.108517_b0255","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"British J. Dermatol."},{"key":"10.1016\/j.intimp.2022.108517_b0260","first-page":"1","article-title":"Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial","author":"Zhao","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108517_b0265","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"New England J. Med."},{"issue":"10093","key":"10.1016\/j.intimp.2022.108517_b0270","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"25","key":"10.1016\/j.intimp.2022.108517_b0275","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"New England J. Med."},{"issue":"10086","key":"10.1016\/j.intimp.2022.108517_b0280","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"5\u20136","key":"10.1016\/j.intimp.2022.108517_b0285","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1759720X18776224","article-title":"The role of the JAK\/STAT signal pathway in rheumatoid arthritis","volume":"10","author":"Malemud","year":"2018","journal-title":"Therap. Adv. Musculoskel. Dis."},{"key":"10.1016\/j.intimp.2022.108517_b0290","article-title":"Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study","author":"Kong","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2022.108517_b0295","article-title":"Comment on: 'Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis' by Kuwabara et al","author":"Rios Rodriguez","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.108517_b0300","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7302","key":"10.1016\/j.intimp.2022.108517_b0305","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2022.108517_b0310","first-page":"917","article-title":"Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis","volume":"123","author":"van den Bogaard","year":"2013","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.intimp.2022.108517_b0315","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaci.2007.04.031","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"120","author":"Howell","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108517_b0320","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.322","article-title":"Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic dermatitis","volume":"8","author":"Tsuji","year":"2017","journal-title":"Cell Death Dis."},{"issue":"15","key":"10.1016\/j.intimp.2022.108517_b0325","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155382","article-title":"Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis","volume":"21","author":"Furue","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.108517_b0330","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"24","key":"10.1016\/j.intimp.2022.108517_b0335","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"New England J. Med."},{"issue":"7","key":"10.1016\/j.intimp.2022.108517_b0340","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol. (Baltimore, Md : 1950)"},{"issue":"12","key":"10.1016\/j.intimp.2022.108517_b0345","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.intimp.2022.108517_b0350","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","article-title":"Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis","volume":"14","author":"Gravallese","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2022.108517_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100866","article-title":"Activation of the interleukin-23\/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis","volume":"80","author":"Zhong","year":"2021","journal-title":"Prog. Ret. Eye Res."},{"issue":"11","key":"10.1016\/j.intimp.2022.108517_b0360","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/j.ajpath.2015.07.017","article-title":"Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis","volume":"185","author":"Kim","year":"2015","journal-title":"Am. J. Pathol."},{"issue":"10","key":"10.1016\/j.intimp.2022.108517_b0365","doi-asserted-by":"crossref","first-page":"479","DOI":"10.5483\/BMBRep.2013.46.10.141","article-title":"The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases","volume":"46","author":"Lee","year":"2013","journal-title":"BMB Rep."},{"issue":"1","key":"10.1016\/j.intimp.2022.108517_b0370","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2022.108517_b0375","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/art.39685","article-title":"Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis","volume":"68","author":"van der Heijde","year":"2016","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)"},{"issue":"7","key":"10.1016\/j.intimp.2022.108517_b0380","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat. Med."},{"issue":"18","key":"10.1016\/j.intimp.2022.108517_b0385","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.intimp.2022.108517_b0390","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2022.108517_b0395","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41584-021-00707-x","article-title":"Interleukin-2 and regulatory T cells in rheumatic diseases","volume":"17","author":"Kolios","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2022.108517_b0400","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1007\/s10620-020-06562-2","article-title":"Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis","volume":"66","author":"Czaja","year":"2021","journal-title":"Dig. Dis. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2022.108517_b0405","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/hep.30061","article-title":"Interleukin 2 Promotes Hepatic Regulatory T Cell Responses and Protects From Biliary Fibrosis in Murine Sclerosing Cholangitis","volume":"68","author":"Taylor","year":"2018","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"6","key":"10.1016\/j.intimp.2022.108517_b0410","first-page":"4883","article-title":"The JAK inhibitor tofacitinib ameliorates immune-mediated liver injury in mice","volume":"20","author":"Wang","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2022.108517_b0415","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/apt.15297","article-title":"Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease","volume":"50","author":"Ma","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"10066","key":"10.1016\/j.intimp.2022.108517_b0420","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2022.108517_b0425","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.14309\/01.ajg.0000590392.63444.97","article-title":"215 Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE","volume":"114","author":"Higgins","year":"2019","journal-title":"Off. J. Am. Coll. Gastroenterol. | ACG"},{"issue":"6","key":"10.1016\/j.intimp.2022.108517_b0430","doi-asserted-by":"crossref","first-page":"S-384-","DOI":"10.1016\/S0016-5085(18)31582-8","article-title":"Sa1758 - Upadacitinib Improves Steroid-Free Clinical and Endoscopic Endpoints in Patients with Crohn's Disease: Data from the Celest Study","volume":"154","author":"Remo","year":"2018","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.intimp.2022.108517_b0435","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study","volume":"12","author":"Sands","year":"2018","journal-title":"J. Crohns Colitis"},{"issue":"suppl_1","key":"10.1016\/j.intimp.2022.108517_b0440","article-title":"P069* TD-1473, a novel, potent, and orally administered, GI-targeted, pan-Janus kinase (JAK) inhibitor","author":"None","year":"2016","journal-title":"J. Crohns Colitis"},{"issue":"19","key":"10.1016\/j.intimp.2022.108517_b0445","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.intimp.2022.108517_b0450","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108517_b0455","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40744-020-00257-w","article-title":"A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis","volume":"8","author":"Edwards","year":"2021","journal-title":"Rheumatol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2022.108517_b0460","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/cpdd.462","article-title":"Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials","volume":"8","author":"Mohamed","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"4","key":"10.1016\/j.intimp.2022.108517_b0465","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcph.1550","article-title":"Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials","volume":"60","author":"Nader","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"Supplement_2","key":"10.1016\/j.intimp.2022.108517_b0470","doi-asserted-by":"crossref","first-page":"S761","DOI":"10.1093\/ecco-jcc\/jjaa003","article-title":"Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease","volume":"14","author":"Siegmund","year":"2020","journal-title":"J. Crohns Colitis"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T15:16:15Z","timestamp":1730819775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":94,"alternative-id":["S1567576922000017"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108517","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108517"}}